Abiopharma

Net Asset Value(s)

FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Alla Felder

インサイトのピボタルfrontMIND試験、タファシタマブ（Monjuvi®/Minjuvi®）併用療法で無増悪生存期間を有意に延長、未治療の高リスクDLBCL患者の病勢進行または死亡リスクを25%低減

FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Michal Tzuk

Shelf offering report for the issuance of deferred debentures F, according to the shelf prospectus dated 31.1.24, orders: 2.6.26

Die zulassungsrelevante frontMIND-Studie von Incyte zeigte, dass die Kombination mit Tafasitamab (Monjuvi®/Minjuvi®) das progressionsfreie Überleben signifikant verlängerte und das Risiko eines Krankheitsfortschritts oder des Todes bei Patienten...

Xeriant Schedules NexBoard™ and NexPatch™ Certification Testing and Shares 30-Minute Internal Timelapse Video of Fire Test Exceeding 2,000°F

Other Report or Announcement

FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Lisa Haimovitz

ZTS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit